Literature DB >> 3386266

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.

D Giudici1, G Ornati, G Briatico, F Buzzetti, P Lombardi, E di Salle.   

Abstract

FCE 24304 (6-methylenandrosta-1,4-diene-3,17-dione), a new irreversible aromatase inhibitor, has been identified and characterized in vitro and in vivo. The compound caused time-dependent inactivation of human placental aromatase with a t1/2 of 13.9 min and ki of 26 nM. When tested in PMSG-treated rats, ovarian aromatase activity was reduced 24 h after dosing by both the s.c. (ED50 1.8 mg/kg) and the oral (ED50 3.7 mg/kg) routes. No interference with 5 alpha-reductase activity nor any significant binding affinity for estrogen receptor was found. Slight binding affinity for the androgen receptor (RBA 0.2% of DHT) was observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3386266     DOI: 10.1016/0022-4731(88)90129-x

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  27 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

Review 3.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 4.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.

Authors:  T Zaccheo; E Di Salle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  The role of aromasin in the hormonal therapy of breast cancer.

Authors:  Magdolna Dank
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.

Authors:  Xin Wang; Selma Masri; Sheryl Phung; Shiuan Chen
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention.

Authors:  Hua Liu; Paul Talalay
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

9.  Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.

Authors:  Christos Markopoulos; Urania Dafni; John Misitzis; Vasilios Zobolas; Evagelos Tzoracoleftherakis; Dimitrios Koukouras; Grigorios Xepapadakis; John Papadiamantis; Basileios Venizelos; Zoh Antonopoulou; Helen Gogas
Journal:  Breast Cancer Res       Date:  2009-06-16       Impact factor: 6.466

10.  Antiproliferative effect of exemestane in lung cancer cells.

Authors:  Angelos Koutras; Efstathia Giannopoulou; Ismini Kritikou; Anna Antonacopoulou; T R Jeffry Evans; Athanasios G Papavassiliou; Haralabos Kalofonos
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.